Biodegradable Nanoparticles as Drug Delivery Systems for Parenteral Administration

Tissue Engineering and Novel Delivery Systems

Volumn , Issue , 2003, Pages 393-422

  Chorny, Michael ^a   Cohen Sacks, Hagit ^a   Fishbein, Ilia ^a   Danenberg, Haim D ^a   Golomb, Gershon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85180875302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203913338-18     Document Type: Chapter

References (216)

1. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of paniculate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Rel 2002; 79:29-40.
2. Allen TM, Moase EH. Therapeutic opportunities for targeted liposomal drug delivery. Adv Drug DelivRev 1996; 21:117-133.
3. Kreuter J. The influence of coating with surfactants on the body distribution of nanoparticles after intravenous injection to rats. Clin Mater 1993; 13:131-134.
4. Leroux JC, Cozens R, Roesel JL, Galli B, Kubel F, Gurny R. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J Pharm Sci 1995; 84:1387-1391.
5. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53:283-318.
6. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001; 47:55-64.
7. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 1998; 87:1305-1307.
8. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11(Suppl 2):S81-S91.
9. Yokoyama M, Okano T. Targetable drug carriers: present status and a future perspective. Adv Drug Deliv Rev 1996; 21:77-80.
10. Muller RH, Jacobs C, Kayser O. Nanosuspensions as paniculate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47: 3-19.
11. Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995; 16:215-233.
12. Leroux JC, Allemann E, Jaeghere FD, Doelker E, Gurny R. Biodegradable nanoparticles-from sustained release formulations to improved site specific drug delivery. J Control Rel 1996; 39: 339-350.
13. Moghimi SM. Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block-copolymers. Adv Drug Deliv Rev 1995; 16:183-193.
14. Stolnik S, Ilium L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995; 16:195-214.
15. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv Drug Deliv Rev 1995; 16:141-155.
16. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28:5-24.
17. Kreuter J. Nanoparticle-based drug delivery systems. J Control Rel 1991; 16:169-176.
18. Rfhova B. Biocompatibility of biomaterials: hemocompatibility, immunocompatibility and biocompatibility of solid polymers and soluble targetable polymeric carriers. Adv Drug Deliv Rev 1996; 21:157-176.
19. Fishbein I, Chorny M, Rabinovich L, Banai S, Gati I, Golomb G. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J Control Rel 2000; 65:221-229.
20. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J Pharm Sci 1998; 87:1229-1234.
21. Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S, Slomkowski S, Golomb G. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 2000; 7: 1896-1905.
22. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 2002; 233:51-59.
23. Panyam J, Zhou W-Z, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-coglycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002; 16:1217-1226.
24. Schwartz JB. Pharmaceutical manufacturing. In: Gennaro AR, Der Manderosian AH, Hanson GR, Medwick T, Popovich NG, Schnaare RL, Schwartz JB, White SH, eds. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott Williams & Wilkins, 2000:780-820.
25. The United States Pharmacopeia. Vol. 24. Philadelphia: National Publishing, 2000.
26. Couvreur P, Couarraze G, Devissaguet JP, Puisieux F. Nanoparticles: preparation and characterization. In: Benita S, ed. Microencapsulation: Methods and Industrial Applications. Vol. 73. New York: Marcel Dekker, 1996:183-211.
27. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel 2001; 70:1-20.
28. Alonso MJ. Nanoparticulate drug carrier technology. In: Lieberman HA, Rieger MM, Banker GS, eds. Pharmaceutical Dosage Forms: Disperse Systems. Vol. 1. New York: Marcel Dekker, 1996: 203-242.
29. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 2001; 47:83-97.
30. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Rel 2002; 78:15-24.
31. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Jnt J Pharm 2001; 224: 159-168.
32. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Rel 2001; 73:255-267.
33. Leong KW, Mao H-Q, Truong-Le VL, Roy K, Walsh SM, August JT. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Rel 1998; 53:183-193.
34. Mao H-Q, Roy K, Truong-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Rel 2001; 70:399-421.
35. Aynie I, Vauthier C, Chacun H, Fattal E, Couvreur P. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1999; 9:301-312.
36. Domb AJ, Kost J, Wiseman DM. Handbook of Biodegradable Polymers. Vol. 7. Amsterdam: Harwood Academic Publishers, 1997:526.
37. Kumar N, Ravikumar MN, Domb AJ. Biodegradable block copolymers. Adv Drug Deliv Rev 2001; 53:23-44.
38. Peracchia MT, Dismaele D, Couvreur P, d'Angelo J. Synthesis of novel MePEGcyanoacrylatchexadecylcyanoacrylate amphiphilic copolymer for nanoparticle technology. Macromolecules 1997; 30:846-851.
39. Peracchia MT, Vauthier C, Desmaele D, Gulik A, Dedieu JC, Demoy M, d'Angelo J, Couvreur P. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm Res 1998; 15:550-556.
40. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser P. Pharmacokinetics and distribution of a biodegradable drug carrier. Int J Pharm 1983; 15:335-345.
41. Van Snick L, Couvreur P, Christiaens-Leyh D, Roland M. Molecular weights of free and drug-loaded nanoparticles. Pharm Res 1985; 1:36-41.
42. Seijo B, Fattal E, Roblot-Treupel L, Couvreur P. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. Int J Pharm 1990; 62:1-7.
43. Ilium L, Khan MA, Mak E, Davis SS. Evaluation of carrier capacity and release characteristics for poly(butyl 2-cyanoacrylate) nanoparticles. Int J Pharm 1986; 30:17-28.
44. da Silveira AM, Ponchel G, Puisieux F, Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrin nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm Res 1998; 15:1051-1055.
45. Guise V, Drouin JY, Benoit J, Mahuteau J, Dumont P, Couvreur P. Vidarabine-loaded nanoparticles: a physicochemical study. Pharm Res 1990; 7:736-741.
46. Grangier JL, Puygrenier M, Gauthier JC, Couvreur P. Nanoparticles as carriers for growth hormone releasing factor (GFR). J Control Rel 1991; 15:3-13.
47. Al Khouri Fallouh N, Roblot-Treupel L, Fessi H, Devissaguet JP, Puisieux F. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharm 1986; 28: 125-132.
48. Rollot JM, Couvreur P, Roblot-Treupel L, Puisieux F. Physicochemical and morphological characterization of polyisobutylcyanoacrylate nanocapsules. J Pharm Sci 1986; 75:361-364.
49. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm Res 2000; 17:707-714.
50. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. Int J Pharm 2001; 214:13-16.
51. Chavany C, Saison-Behmoaras T, Le Doan T, Puisieux F, Couvreur P, Helene C. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm Res 1994; 11:1370-1378.
52. Nakada Y, Fattal E, Foulquier M, Couvreur P. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm Res 1996; 13:38-43.
53. De Keyser J-L, Poupaert JH, Dumont P. Poly(diethyl methylidenemalonate) nanoparticles as a potential drug carrier: preparation, distribution and elimination after intravenous and peroral administration in mice. J Pharm Sci 1991; 80:67-70.
54. Lescure F, Seguin C, Breton P, Bourrinet P, Roy D, Couvreur P. Preparation and characterization of novel po!y(methylidene malonate 2.1.2)-made nanoparticles. Pharm Res 1994; 11:1270-1277.
55. Brigger I, Chaminade P, Marsaud V, Appel M, Besnard M, Gurny R, Renoir M, Couvreur P. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int J Pharm 2001; 214:37-42.
56. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, Appel M, d'Angelo J, Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Rel 1999; 60:121-128.
57. Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J, Williams A, Andreux JP, Dormont D, Couvreur P. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases, J Neurosci Methods 2001; 111:151-155.
58. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001; 18:1157-1166.
59. (Pekarek) Leach KJ, Mathiowitz E. Degradation of double-walled polymer microspheres of PLLA and P(CPP:SA)20:80. I. In vitro degradation. Biomaterials 1998; 19:1973-1980.
60. Belbella A, Vauthier C, Fessi H, Devissaguet JP, Puisieux F. In vitro degradation of nanospheres from poly(DX-lactides) of different molecular weights and polydispersities. Int J Pharm 1996; 129: 95-102.
61. Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, Maincent P. Stability study of nanoparticles of poly(>-caprolactone), poly(DX-lactide) andpoly(DX-lactide-roglycolide). Biomaterials 1996; 17:2191-2197.
62. Santos CA, Freedman BP, Leach KJ, Press DL, Scarpulla M, Mathiowitz E. Poly(fumaric-ro-sebacic anhydride). A degradation study as evaluated by FTIR, DSC, GPC and X-ray diffraction. J Controlled Release 1999; 60:11-22.
63. Tabata Y, Gutta S, Langer R. Controlled delivery systems for proteins using polyanhydride micro-spheres. Pharm Res 1993; 10:487-496.
64. Tabata Y, Langer R. Polyanhydride microspheres that display near-constant release of water-soluble model drug compounds. Pharm Res 1993; 10:391-399.
65. Lacasse FX, Filion MC, Phillips NC, Escher E, McMullen IN, Hildgen P. Influence of surface properties at biodegradable microsphere surfaces: effects or ma protein adsorption and phagocytosis. PharmRes 1998; 15:312-317.
66. Domb AJ, Elmalak O, Shastri VB, Ta-Shma Z, Masters DM, Ringel I, Teomim D, Langer R. Polyanhydrides. In: Domb AJ, Kost J, Wiseman DM, eds. Handbook of Biodegradable Polymers. Vol. 7. Amsterdam: Harwood Academic Publishers, 1997:135-159.
67. Perrin DA, English JP. Polyglycolide and polylactide. In: Domb AJ, Kost J, Wiseman DM, eds. Handbook of Biodegradable Polymers. Vol. 7. Amsterdam: Harwood Academic Publishers, 1997: 3-26.
68. Pekarek KJ, Jacobs JS, Mathiowitz E. One-step preparation of double-walled microspheres. Adv Mater 1994; 6:684-687.
69. Pekarek KJ, Dyrud MJ, Ferrer K, Jong YS, Mathiowitz E. In vitro and in vivo degradation of double-walled polymer microspheres. J Control Rel 1996; 40:169-178.
70. Venier-Julienne MC, Benoit JP. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm Acta Helv 1996; 71:121-128.
71. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 1998; 24:1113-1128.
72. Sah H. Microencapsulation techniques using ethyl acetate as a dispersed solvent: effects of its extraction rate on characteristics of PLGA microspheres. J Control Rel 1997; 47:233-245.
73. Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ. Protein encapsulation within poly(ethylene glycoi)-coated nanospheres. II. Controlled release properties. J Biomed Mater Res 1999; 47:388-395.
74. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Preparation and characterization of protein C-loaded PLA nanoparticles. J Control Rel 1999; 60:179-188.
75. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrude P, Vigneron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Rel 1998; 50:31-40.
76. Gopferich A, Alonso MJ, Langer R. Development and characterization of microencapsulated micro-spheres. PharmRes 1994; 11:1568-1574.
77. Li X, Zhang Y, Yan R, Jia W, Yuan M, Deng X, Huang Z. Influence of process parameters on the protein stability encapsulated in poly-DL-lactide-poly(ethylene glycol) microspheres. J Control Rel 2000; 68:41-52.
78. Li W-I, Anderson KW, DeLuca PP. Kinetic and thermodynamic modeling of the formation of polymeric microspheres using solvent extraction/evaporation method. J Control Rel 1995; 37: 187-198.
79. Li W-I, Anderson KW, Mehta RC, DeLuca PP. Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method. J Control Rel 1995; 37:199-214.
80. Song CX, Labhasetwar V, Murphy H, Qu X, Hunphrey WR, Shebuski RJ, Levy RJ. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Rel 1997; 43:197-212.
81. Feng S, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J Control Rei 2001; 71:53-69.
82. Gorner T, Gref R, Michenot D, Sommer F, Tran MN, Dellacherie E. Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J Control Rel 1999; 57:259-268.
83. ®). J Control Rel 2002; 80:129-144.
84. Ueda M, Kreuter J. Optimization of the preparation of loperamide-loaded poly (L-lactide) nanoparticles by high pressure emulsification-solvent evaporation. J Microencapsul 1997; 14:593-605.
85. Vandervoort J, Ludwig A. Preparation factors affecting the properties of polylactide nanoparticles: a factorial design study. Pharmazie 2001; 56:484-488.
86. Herrmann J, Bodmeier R. Somatostatin containing biodegradable microspheres prepared by a modified solvent evaporation method based on w/o/wmultipleemulsions. IntJPharm 1995; 126:129-138.
87. Lemoine D, Preat V. Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J Control Rel 1998; 54:15-27.
88. Labhasetwar V, Bonadio J, Goldstein SA, Levy RJ. Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model. Colloids Surfaces B: Biointerfaces 1999; 16:281-290.
89. Izumikawa S, Yoshioka S, Aso Y, Takeda Y. Preparation of poly(L-lactide) microspheres of different crystalline morphology and effect of crystalline morphology on drug release rate. J Control Rel 1991; 15:133-140.
90. Liggins RT, Burt HM. Paclitaxel loaded poly(L-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers. Int J Pharm 2001; 222:19-33.
91. Polakovic M, Gorner T, Gref R, Dellacherie E. Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. J Control Rel 1999; 60:169-177.
92. O'Donnell PB, McGinity JW. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev 1997; 28:25-42.
93. Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol) micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur J Pharm Biopharm 2001; 51:111-118.
94. Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm 2002; 238:77-92.
95. Verrecchia T, Huve P, Bazile D, Veillard M, Spenlehauer G, Couvreur P. Adsorption/desorption of human serum albumin at the surface of polyOactic acid nanoparticles prepared by a solvent evaporation process. J Biomed Mater Res 1993; 27:1019—1028.
96. Scholes PD, Coombes AGA, Ilium L, Davis SS, Vert M, Davies MC. The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery. J Control Rel 1993; 25: 145-153.
97. Birnbaum DT, Kosmala JD, Brannon-Peppas L. Optimization of preparation techniques for poly(lactic acid-co-glycolic acid) nanoparticles. J Nanoparticie Res 2000; 2:173-181.
98. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. Pseudolatex preparation using a novel emulsion-diffusion process involving direct displacement of partially water-miscible solvents by distillation. Int J Pharm 1999; 188:155-164.
99. Nihant N, Schugens C, Grandfils C, Jerome R, Teyssie P. Polylactide microparticles prepared by double emulsion/evaporation technique. I. Effect of primary emulsion stability. Pharm Res 1994; 11:1479-1484.
100. Soriano I, Delgado A, Diaz RV, Evora C. Use of surfactants in polylactic acid protein microspheres. Drug Dev Ind Pharm 1995; 21:549-558.
101. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization, J Pharm Sci 1999; 88: 126-130.
102. Hueper WC. Carcinogenic studies on water-soluble and insoluble macromolecules. Arch Pathol 1959; 67:589-617.
103. Yamaoka T, Tabata Y, Ikada Y. Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration. J Pharm Pharmacol 1995; 47:479-486.
104. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly(Dxlactide-ra-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Rel 2002; 82:105-114.
105. Scholes PD, Coombes AG, Ilium L, Davis SS, Watts JF, Ustariz C, Vert M, Davies MC. Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS, J Control Rel 1999; 59:261-278.
106. Allemann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 1993; 10: 1732-1737.
107. Konan YN, Gurny R, Allemann E. Preparation and characterization of sterile and freeze-dried sub200-nm nanoparticles. Int J Pharm 2002; 233:239-252.
108. Quintanar-Guerrero D, Ganem-Quintanar A, Allemann E, Fessi H, Doelker E. Influence of the stabilizer coating layer on the purification and freeze-drying of poly(o, L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique. J Microencapsul 1998; 15:107—119.
109. ® from poly(D, L-lactic acid) nanoparticles coated with albumin or polyvinyl alcohol in model digestive fluids (USP XXII). J Control Rel 1997; 44:227-236.
110. Verrecchia T, Spenlehauer G, Bazile D, Murry-Brelier A, Archimbaud Y, Vieillard M. Non-stealth (poly(lactic acid albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J Control Rel 1995; 36:49-61.
111. Bazile DV, Ropert C, Huve P, Verrecchia T, Marlard M, Frydman A, Veillard M, Spenlehauer G. Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992; 13:1093-1102.
112. Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1, 2-dipalmitoylphosphatidylcholine. J Control Rel 1998; 51:143-152.
113. ®) loaded poly(lactic-co-glycolic acid) manospheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Rel 2001; 76:239-254.
114. Bitz C, Doelker E. Influence of the preparation method on residual solvents in biodegradable micro-spheres. Int J Pharm 1996; 131:171-181.
115. Allemann E, Gurny R, Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size. Int J Pharm 1992; 87:247-253.
116. Ibrahim H, Bindschaedler C, Doelker E, Buri P, Gurny R. Aqueous nanodispersions prepared by a salting-out process. Int J Pharm 1992; 87:239-246.
117. Zweers ML, Engbers GHM, Grijpma DW, Feijen J. Biodegradable nanospheres for local drug delivery to prevent restenosis after baloon angioplasty. J Control Rel 2001; 72:225-309.
118. De Jaeghere F, Allemann E, Leroux JC, Stevels W, Feijen J, Doelker E, Gurny R. Formulation and lyoprotection of poly(lactic acid-coethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm Res 1999; 16:859-866.
119. De Jaeghere F, Allemann E, Feijen J, Kissel T, Doelker E, Gurny R. Cellular uptake of PEO surface-modified nanoparticles: evaluation of nanoparticles made of PLA: PEO diblock and triblock copolymers. J Drug Target 2000; 8:143-153.
120. De Jaeghere F, Allemann E, Feijen J, Kissel T, Doelker E, Gurny R. Freeze-drying and lyopreservation of diblock and triblock poly(lactic acid)-poly(ethylene oxide) (PLA-PEO) copolymer nanoparticles. Pharm Dev Technol 2000; 5:473-483.
121. Berton M, Allemann E, Stein C A, Gurny R. Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex. Eur J Pharm Sci 1999; 9:163-170.
122. Quintanar-Guerrero D, Fessi H, Allemann E, Doelker E. Influence of stabilizing agents and preparative variables on the formation of poly(D, L-lactic acid) nanoparticles by an emulsification-diffusion technique. Int J Pharm 1996; 143:133-141.
123. Berton M, Benimetskaya L, Allemann E, Stein CA, Gurny R. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur J Pharm Biopharm 1999; 47:119-123.
124. Delie F, Berton M, Allemann E, Gurny R. Comparison of two methods of encapsulation of an oligonucleotide into poly(o, L-lactic acid) particles. Int J Pharm 2001; 214:25-30.
125. Quintanar-Guerrero D, Allemann E, Doelker E, Fessi H. Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm Res 1998; 15:1056-1062.
126. Trotta M, Gallarate M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Rel 2001; 76:119-128.
127. Wehrle P, Magenheim B, Benita S. The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design. Eur J Pharm Biopharm 1995; 41:19-26.
128. Ford J, Woolfe J, Florence AT. Nanospheres of cyclosporin A: poor oral absorption in dogs. Int J Pharm 1999; 183:3-6.
129. Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Tnd Phann 1999; 25: 471-476.
130. Govender T, Stolnik S, Garnett MC, Ilium L, Davis SS. PLGA nanoparticles prepared by nanopreci­ pitation: drug loading and release studies of a water soluble drug. J Control Rei 1999; 57:171-185.
131. Govender T, Riley T, Stolnik S, Garnett MC, Ilium L, Davis SS. PLA-PEG nanoparticles for site specific delivery: drug incorporation study. J Controlled Release 2000; 64:318-319.
132. Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Ilium L, Davis SS. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Phann 2000; 199:95-110.
133. Chacon M, Berges L, Molpeceres J, Aberturas MR, Guzman M. Optimized preparation of poly(D.L­ lactic-glycolic) microspheres and nanoparticles for oral administration. Int J Phann 1996; 141: 81-91.
134. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K. Effect of dose on the biodistribution and phannacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001; 221:143-152.
135. Verger MLL, Fluckiger L, Kim YI, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998; 46:137-143.
136. Stolnik S, Garnett MC, Davies MC, Ilium L, Bousta M, Vert M, Davis SS. The colloidal properties of surfactant-free biodegradable nanospheres from poly(β-malic acid-co-benzyl malate)s and poly(lactic acid-co-glycolide). Colloids and Surfaces A: Physicochem and Eng Aspects 1995; 97: 235-245.
137. Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas MR. Stability and freeze-drying of cyclosporine loaded poly(D.L lactide-glycolide) carriers. Eur J Pharm Sci 1999; 8:99-107.
138. Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Rel 2002.
139. Guzman M, Molpeceres J, Garcia F, Aberturas MR, Rodriguez M. Fonnation and characterization of cyclosporine-loaded nanoparticles. J Pharm Sci 1993; 82:498-502.
140. Magenheim B, Levy MY, Benita S. A new in vitro technique for the evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Phann 1993; 94: 115-123.
141. Molpccercs J, Guzman M, Aberturas MR, Chacon M, Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticlcs by solvent displacement. J Pharm Sci 1996; 85:206-213.
142. Murakami H, Kawashima A, Niwa T, Hino T, Takeuchi H, Kobayashi M. Influence of degrees of hydrolyzation and polymerization of poly(vinyl alcohol) on the preparation and properties of po­ ly(DL-lactide-co-glycolide) nanoparticles. Int J Phann 1997; 149:43-49.
143. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(DL-lactide-co-gly­ colide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Phann 1999; 187:143-152.
144. Kawashima Y, Yamamoto H, Takeuchi H, Hino T, Niwa T. Properties of a peptide containing DL­ lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Phann Biopharm 1998; 45:41-48.
145. Niwa T, Takeuchi H, Nino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D.L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Controlled Release 1993; 25:89-98.
146. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. In vitro drug release behavior ofD.L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J Pharm Sci 1994; 83:727-732.
147. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 1996; 85: 530-536.
148. Magenhcim B, Benita S. Elucidation of the indomethacin in vitro release mechanism from polylactic acid nanoparticles. Pharm Res 1993; 10:S-187.
149. Hirosue S, Millier BG, Mulligan RC, Langer R. Plasmid DNA encapsulation and release from solvent diffusion nanospheres. J Control Rei 2001; 70:231-242.
150. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Rei 2001; 75: 211-224.
151. Chorny M, Fishbein I, Danenberg HD, Golomb G. Study of the drug release mechanism from tyrphostin AG-1295 loaded nanospheres using in situ and external sink methods. J Control Rei 2002.
152. Fishbein I, Chorny M, Banai S, Levitzki A, Danenberg HD, Gao J, Chen X, Moerman E, Gati I, Goldwasser V, Golomb G. Formulation and delivery mode affect disposition and activity of tyrphos­ tin-loaded nanoparticles in the rat carotid model. Atherosclcr Thromb Vase Biol 2001; 21: 1434-1439.
153. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989; 55:Rl-R4.
154. Ammoury N, Fessi H, Devissaguet JP, Puisieux F, Benita S. In vitro release kinetic pattern of indomethacin from poly(o, L-lactide) nanocapsules. J Pharm Sci 1990; 79:763-767.
155. Mosqueira VCF, Legrand P, Pinto-Alphandary H, Puisieux F, Barratt G. Poly(D.L-lactide) nanocap­ sules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. J Pharm Sci 2000; 89:614-626.
156. Magalhaes NS, Fcssi H, Puisieux F, Benita S, Seiller M. An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofi­ bride. J Microencapsul 1995; 12:195-205.
157. Bittner B, Mader K, Kroll C, Borchert HH, Kissel T. Tetracycline-HCl-loaded poly(oL-lactide-co­ glycolide) microspheres prepared by a spray drying technique: influence of gamma-irradiation on radical formation and polymer degradation. J Control Rei 1999; 59:23-32.
158. Hausberger AG, Kenley RA, DeLuca PP. Gamma irradiation effects on molecular weight and in vitro degradation of poly(o, L-lactide-co-glycolide) microparticles. Pharm Res 1995; 12:851-856.
159. Montanari L, Cilurzo F, Valvo L, Faucitano A, Buttafava A, Groppo A, Genta I, Conti B. Gamma irradiation effects on stability of poly(lactide-co-glycolide) microspheres containing clonazepam. J Control Rei 2001; 75:317-330.
160. Shen ZR, Zhu JH, Ma Z, Wang F, Wang ZY. Preparation of biodegradable microsphercs of testoster­ one with poly(D.L-lactide-co-glycolide) and test of drug release in vitro. Artif Cells Blood Substit Immobil Biotechnol 2000; 28:57-64.
161. Allemann E, Gurny R, Leroux JC. Biodegradable nanoparticles of poly(lactic acid) and poly(lactic­ co-glycolic acid) for parenteral administration. In: Liberman HA, Rieger MM, Banker GS, eds. Pharmaceutical Dosage Forms: Disperse Systems: Marcel Dekker, 1996:163-194.
162. Konan YN, Gurny R, Allemann E. Preparation and characterization of sterile and freeze-dried sub200-nm nanoparticles. Int J Pharm 2002; 233:239-252.
163. Quintanar-Guerrero D, Ganem-Quintanar A, Allemann E, Fessi H, Doelker E. Influence of the stabilizer coating layer on the purification and freeze-drying of poly(o, L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique. J Microencapsul 1998; 15:107—119.
164. Landry FB, Bazile DV, Spenlehauer G, Veillard M, Kreuter J. Release of the fluorescent marker Prodan® from poly(D, L-lactic acid) nanoparticles coated with albumin or polyvinyl alcohol in model digestive fluids (USP XXII). J Control Rel 1997; 44:227-236.
165. Verrecchia T, Spenlehauer G, Bazile D, Murry-Brelier A, Archimbaud Y, Vieillard M. Non-stealth (poly(lactic acid albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J Control Rel 1995; 36:49-61.
166. Bazile DV, Ropert C, Huve P, Verrecchia T, Marlard M, Frydman A, Veillard M, Spenlehauer G. Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992; 13:1093-1102.
167. Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1, 2-dipalmitoylphosphatidylcholine. J Control Rel 1998; 51:143-152.
168. Mu L, Feng SS. Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly(lactic-co-glycolic acid) manospheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Rel 2001; 76:239-254.
169. Bitz C, Doelker E. Influence of the preparation method on residual solvents in biodegradable micro-spheres. Int J Pharm 1996; 131:171-181.
170. Allemann E, Gurny R, Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size. Int J Pharm 1992; 87:247-253.
171. Ibrahim H, Bindschaedler C, Doelker E, Buri P, Gurny R. Aqueous nanodispersions prepared by a salting-out process. Int J Pharm 1992; 87:239-246.
172. Zweers ML, Engbers GHM, Grijpma DW, Feijen J. Biodegradable nanospheres for local drug delivery to prevent restenosis after baloon angioplasty. J Control Rel 2001; 72:225-309.
173. De Jaeghere F, Allemann E, Leroux JC, Stevels W, Feijen J, Doelker E, Gurny R. Formulation and lyoprotection of poly(lactic acid-coethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm Res 1999; 16:859-866.
174. De Jaeghere F, Allemann E, Feijen J, Kissel T, Doelker E, Gurny R. Cellular uptake of PEO surface-modified nanoparticles: evaluation of nanoparticles made of PLA:PEO diblock and triblock copolymers. J Drug Target 2000; 8:143-153.
175. De Jaeghere F, Allemann E, Feijen J, Kissel T, Doelker E, Gurny R. Freeze-drying and lyopreservation of diblock and triblock poly(lactic acid)-poly(ethylene oxide) (PLA-PEO) copolymer nanoparticles. Pharm Dev Technol 2000; 5:473-483.
176. Berton M, Allemann E, Stein C A, Gurny R. Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex. Eur J Pharm Sci 1999; 9:163-170.
177. Quintanar-Guerrero D, Fessi H, Allemann E, Doelker E. Influence of stabilizing agents and preparative variables on the formation of poly(D, L-lactic acid) nanoparticles by an emulsification-diffusion technique. Int J Pharm 1996; 143:133-141.
178. Berton M, Benimetskaya L, Allemann E, Stein CA, Gurny R. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur J Pharm Biopharm 1999; 47:119-123.
179. Delie F, Berton M, Allemann E, Gurny R. Comparison of two methods of encapsulation of an oligonucleotide into poly(o, L-lactic acid) particles. Int J Pharm 2001; 214:25-30.
180. Quintanar-Guerrero D, Allemann E, Doelker E, Fessi H. Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm Res 1998; 15:1056-1062.
181. Trotta M, Gallarate M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Rel 2001; 76:119-128.
182. Wehrle P, Magenheim B, Benita S. The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design. Eur J Pharm Biopharm 1995; 41:19-26.
183. Ford J, Woolfe J, Florence AT. Nanospheres of cyclosporin A: poor oral absorption in dogs. Int J Pharm 1999; 183:3-6.
184. Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Tnd Phann 1999; 25: 471-476.
185. Govender T, Stolnik S, Garnett MC, Ilium L, Davis SS. PLGA nanoparticles prepared by nanopreci­ pitation: drug loading and release studies of a water soluble drug. J Control Rei 1999; 57:171-185.
186. Govender T, Riley T, Stolnik S, Garnett MC, Ilium L, Davis SS. PLA-PEG nanoparticles for site specific delivery: drug incorporation study. J Controlled Release 2000; 64: 318-319.
187. Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Ilium L, Davis SS. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Phann 2000; 199:95-110.
188. Chacon M, Berges L, Molpeceres J, Aberturas MR, Guzman M. Optimized preparation of poly(D.L­ lactic-glycolic) microspheres and nanoparticles for oral administration. Int J Phann 1996; 141: 81-91.
189. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K. Effect of dose on the biodistribution and phannacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001; 221:143-152.
190. Verger MLL, Fluckiger L, Kim YI, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998; 46:137-143.
191. Stolnik S, Garnett MC, Davies MC, Ilium L, Bousta M, Vert M, Davis SS. The colloidal properties of surfactant-free biodegradable nanospheres from poly(β-malic acid-co-benzyl malate)s and poly(lactic acid-co-glycolide). Colloids and Surfaces A: Physicochem and Eng Aspects 1995; 97: 235-245.
192. Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas MR. Stability and freeze-drying of cyclosporine loaded poly(o.L lactide-glycolide) carriers. Eur J Pharm Sci 1999; 8:99-107.
193. Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Rel 2002.
194. Guzman M, Molpeceres J, Garcia F, Aberturas MR, Rodriguez M. Fonnation and characterization of cyclosporine-loaded nanoparticles. J Pharm Sci 1993; 82:498-502.
195. Magenheim B, Levy MY, Benita S. A new in vitro technique for the evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Phann 1993; 94: 115-123.
196. Molpccercs J, Guzman M, Aberturas MR, Chacon M, Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticlcs by solvent displacement. J Pharm Sci 1996; 85:206-213.
197. Murakami H, Kawashima A, Niwa T, Hino T, Takeuchi H, Kobayashi M. Influence of degrees of hydrolyzation and polymerization of poly(vinyl alcohol) on the preparation and properties of po­ ly(DL-lactide-co-glycolide) nanoparticles. Int J Phann 1997; 149:43-49.
198. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(rn.-lactide-co-gly­ colide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Phann 1999; 187:143-152.
199. Kawashima Y, Yamamoto H, Takeuchi H, Hino T, Niwa T. Properties of a peptide containing DL­ lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Phann Biopharm 1998; 45:41-48.
200. Niwa T, Takeuchi H, Nino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D.L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Controlled Release 1993; 25:89-98.
201. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. In vitro drug release behavior ofD.L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsificationsolvent diffusion method. J Pharm Sci 1994; 83:727-732.
202. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 1996; 85: 530-536.
203. Magenhcim B, Benita S. Elucidation of the indomethacin in vitro release mechanism from polylactic acid nanoparticles. Pharm Res 1993; 10:S-187.
204. Hirosue S, Millier BG, Mulligan RC, Langer R. Plasmid DNA encapsulation and release from solvent diffusion nanospheres. J Control Rei 200 I; 70:231-242.
205. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Rei 2001; 75: 211-224.
206. Chorny M, Fishbein I, Danenberg HD, Golomb G. Study of the drug release mechanism from tyrphostin AG-1295 loaded nanospheres using in situ and external sink methods. J Control Rei 2002.
207. Fishbein I, Chorny M, Banai S, Levitzki A, Danenberg HD, Gao J, Chen X, Moerman E, Gati I, Goldwasser V, Golomb G. Formulation and delivery mode affect disposition and activity of tyrphos­ tin-loaded nanoparticles in the rat carotid model. Atherosclcr Thromb Vase Biol 2001; 21: 1434-1439.
208. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989; 55:Rl-R4.
209. Ammoury N, Fessi H, Devissaguet JP, Puisieux F, Benita S. In vitro release kinetic pattern of indomethacin from poly(o, L-lactide) nanocapsules. J Pharm Sci 1990; 79:763-767.
210. Mosqueira VCF, Legrand P, Pinto-Alphandary H, Puisieux F, Barratt G. Poly(D.L-lactide) nanocap­ sules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. J Pharm Sci 2000; 89: 614-626.
211. Magalhaes NS, Fcssi H, Puisieux F, Benita S, Seiller M. An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofi­ bride. J Microencapsul 1995; 12:195-205.
212. Bittner B, Mader K, Kroll C, Borchert HH, Kissel T. Tetracycline-HCl-loaded poly(oL-lactide-co­ glycolide) microspheres prepared by a spray drying technique: influence of gamma-irradiation on radical formation and polymer degradation. J Control Rei 1999; 59:23-32.
213. Hausberger AG, Kenley RA, DeLuca PP. Gamma irradiation effects on molecular weight and in vitro degradation of poly(o, L-lactide-co-glycolide) microparticles. Pharm Res 1995; 12:851-856.
214. Montanari L, Cilurzo F, Valvo L, Faucitano A, Buttafava A, Groppo A, Genta I, Conti B. Gamma irradiation effects on stability of poly(lactide-co-glycolide) microspheres containing clonazepam. J Control Rei 2001; 75:317-330.
215. Shen ZR, Zhu JH, Ma Z, Wang F, Wang ZY. Preparation of biodegradable microsphercs of testoster­ one with poly(D.L-lactide-co-glycolide) and test of drug release in vitro. Artif Cells Blood Substit Immobil Biotechnol 2000; 28:57-64.
216. Allemann E, Gurny R, Leroux JC. Biodegradable nanoparticles of poly(lactic acid) and poly(lactic­ co-glycolic acid) for parenteral administration. In: Liberman HA, Rieger MM, Banker GS, eds. Pharmaceutical Dosage Forms: Disperse Systems: Marcel Dekker, 1996:163-194.